Andrew Hong, MD, is a physician scientist and pediatric oncologist at the Dana-Farber / Boston Children's Cancer and Blood Disorders Center. His research focuses on genetic analyses and functional genomics in kidney cancers and the creation of rare cancer models.
Charles Keller, MD is the Scientific Director and member of the Children’s Cancer Therapy Development Institute (cc-TDI). He is a member of the soft tissue sarcoma (STS) committee of Children’s Oncology Group and has also recently completed a 5-year rotation as a Standing Member of the National Cancer Institute NCI-I Study Section. Charles has authored over 100 scientific publications and is a recognized expert in the biology of childhood sarcomas and the preclinical investigation of childhood cancers. His research focusses on developing more effective and less toxic therapies for pediatric cancers, with a special interest in advanced disease that has spread beyond the initial location of the cancer or which makes the tumor unresectable.
Marry van den Heuvel-Eibrink MD, PhD is a professor of pediatric oncology at the University of Utrecht Princess Maxima Center for Pediatric Oncology. She is Chair of the international Working Group for MDS and JMML(EWOG-MDS), Co-chair of the international renal tumor disease committee (SIOP-RTSG), Chair of the national DCOG renal tumor committee, and steering committee member of the DCOG late effects consortium. Her research focusses on translational research with an emphasis on renal tumors.